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Abstract Overexpression of EGFR and c-erbB2 frequently
occurs in human breast cancers, correlating with poor prognosis.
Here we show that overexpression of EGFR and c-erbB2 in cell
lines increases cell migration, an important step in metastasis
formation. The effect of EGFR on migration is dependent on the
addition of EGF to the cells. In contrast, c-erbB2 seems to act
independently of its ligand in these assays. Overexpression of this
receptor is sufficient to induce cell migration. In addition, we
investigated the involvement of a number of signal transduction
pathways known to be activated by the EGFR. We found that
inactivation of MAPKK results in a decreased migration, while
inactivation of PI3K increases migration.
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1. Introduction
The epidermal growth factor receptor (EGFR) and c-erbB2
are members of the type 1 family of tyrosine kinase cell sur-
face receptors. Activation of the EGFR can lead to prolifer-
ation or di¡erentiation depending on the cell type [1]. Upon
ligand binding, the EGFR can homodimerize, or form heter-
odimers with the other members of the type I family [2].
Receptor dimerization leads to activation of the EGFR and
subsequently to cross-phosphorylation of tyrosine residues in
the cytoplasmic tail of the receptor [1]. These phosphotyrosine
residues in the carboxy-terminus of the receptor serve as high
a⁄nity sites for proteins that, in turn, transmit the growth
factor signal inside the cell [3]. Examples are phospholipase
C-Q [4], the 85 kDa subunit of phosphatidylinositol-3 kinase
[5], c-Src tyrosine kinases [6], and Grb2 [7]. Although the
possible ligand for c-erbB2 has not been identi¢ed yet, the
C-terminus of the receptor can be phosphorylated by cross-
phosphorylation through EGFR. Several reports have de-
scribed the puri¢cation of a biologically active ligand, termed
heregulin or neu di¡erentiation factor. However, direct bind-
ing of this factor to c-erbB2 has not been demonstrated (re-
viewed in [8]).
Overexpression of the EGFR and also c-erbB2 has been
found in a number of human malignancies, including bladder
cancer [9], colon carcinoma [10], and lung cancer [11]. In
breast cancer, high levels of the EGFR [12] and c-erbB2 [13]
have been shown to correlate strongly with poor prognosis.
An apparently additive e¡ect has been described of EGFR
and c-erbB2 overexpression on patient prognosis [13,14].
A common mechanism for c-erbB2 overexpression in breast
cancer is gene ampli¢cation, but increased c-erbB2 protein is
also found in some cancers with normal gene copy number
[13]. It has been shown that overexpression of c-erbB2 alone is
su⁄cient to cause malignant transformation [15]. Unlike c-
erbB2, however, EGFR overexpression is almost never due
to gene ampli¢cation, rather increased receptor synthesis ap-
pears to be responsible [16]. EGFR, even when signi¢cantly
overexpressed, does not transform unless EGF or TGF-K are
provided [17]. The expression of EGF, TGF-K, and another
EGF family member, named amphiregulin, is often increased
in breast cancers [18].
The ¢nal stage of tumor progression is formation of meta-
stases. Metastatic spread of tumors is a consequence of a
series of events in which growth factors could be involved.
Sequentially, tumor cells must proliferate, lose their contacts
with neighboring cells, pass through the vessel wall, enter the
blood stream, in¢ltrate the target organ and form a secondary
tumor [19]. During all these processes, tumor cells are sub-
jected to a variety of environmental controls, including
growth factors from the host or from the tumor itself. Accu-
mulating evidence suggests that activation of the EGFR by
EGF or TGF-K may support the metastatic capacity of tumor
cells.
In the present report we studied the e¡ects of EGFR and c-
erbB2 overexpression and activation on cell migration, an
important step in the metastatic process. We used human
breast cancer cells expressing EGFR and NIH3T3 cells ex-
pressing EGFR, EGFR/c-erbB2 chimerae, or c-erbB2. The
results show that cell migration of human breast cancer cells
that overexpress EGFR is highly (20-fold) increased upon
EGF incubation. Using inhibitors for MAPKK and PI3K,
we found that both MAPK and PI3K pathways might be
involved in this phenomenon.
In NIH3T3 cells overexpressing EGFR or c-erbB2, cell mi-
gration is also increased. Our results indicate that cell migra-
tion of EGFR overexpressing cells is only increased after EGF
incubation, whereas overexpression of c-erbB2 alone is su⁄-
cient to induce cell migration.
These results show that overexpression of both EGFR and
c-erbB2 induces in vitro cell migration, a process that is in-
volved in the metastatic spread of tumor cells.
2. Material and methods
2.1. Cell culture
ZR75-1 human breast cancer cells, transfected with the EGF recep-
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tor (ZR11) or the empty vector (ZR9b11) [20], were kindly donated by
E. Valverius (Uppsala, Sweden). HER13 and HER14 cells (NIH3T3
cells transfected with wild type EGFR [21]) were kindly donated by J.
Boonstra (Utrecht, The Netherlands). LTR-EN2 and NEN37 cells
(NIH3T3 cells transfected with a EGFR/c-erbB2 chimera [22]) were
kindly donated by K. Alitalo (Helsinki, Finland). H3 and 3.4 cells
(NIH3T3 cells expressing c-erbB2 under the control of a tetracycline-
responsive promoter and cells expressing c-erbB2 from a constitutive
SV40 early promoter respectively [23]) were kindly donated by T.
Beckers (Asta Medica AG, Frankfurt/Main, Germany). NIH3T3 cells
were obtained from the American Tissue Culture Collection.
Cells were routinely cultured in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% heat-inactivated newborn calf serum,
2 mM L-glutamine, 100 U/ml penicillin and 100 Wg/ml streptomycin,
in a 5% CO2 humidi¢ed atmosphere at 37‡C.
All cell lines expressed the respective receptor or chimera, which
could be phosphorylated, as was con¢rmed by immunoprecipitation
of the receptor/chimera followed by Western blotting experiments us-
ing anti-EGFR or anti-c-erbB2 antibodies or using anti-PTyr anti-
bodies (data not shown).
2.2. Cell migration assay
We used Transwell cell culture chambers (Costar 3422, Cambridge,
MA) containing ¢lters with 12 Wm pore size. The ¢lters were either left
untreated or coated with extracellular matrix (70 Wl of a 1:7.5 dilution
in H2O; ECM is a reconstituted basement membrane extract from the
EHS (Engelbreth-Holm-Swarm) sarcoma, containing laminin, colla-
gen type IV, and heparin sulfate proteoglycan, Harbor Bio-products,
Norwood, MA). At the bottom of the lower compartment di¡erent
concentrations of EGF dissolved in 100 Wl low-melting agarose were
placed as a chemoattractant. The EGF/agarose solution was added
along the sides of the lower compartment and 1500 Wl culture medium
was added. Cell suspensions (5U104 cells/500 Wl culture medium) were
added to the upper compartment. After 48 h the number of migrated
cells at the bottom of the lower compartment was counted under a
phase-contrast microscope in 10 random ¢elds at a 100U magni¢ca-
tion. The assays were performed in triplicate and repeated three times.
3. Results
In order to study the e¡ect of EGFR and c-erbB2 over-
expression on the metastatic process, we developed an in vitro
cell migration system. In vivo, tumor cells have to overcome
barriers, like the vessel wall, in order to form a secondary
tumor. To mimic this situation we used Transwell cell culture
chambers, that contain ¢lters with 12 Wm pore size. We coated
these ¢lters with extracellular matrix (ECM) components.
Since activation of EGFR by its ligand EGF has been de-
scribed to induce metastatic spread of tumor cells, we studied
the induction of cell migration by EGF. Therefore, we placed
EGF, dissolved in low-melting agarose, as a chemoattractant
at the bottom of the lower chamber (see Material and Meth-
ods). This approach worked far better than just adding EGF
in culture medium in the lower compartment, since much
more cells migrated when EGF was ¢rst dissolved in agarose
(not shown).
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Fig. 1. In vitro assay for cell migration. A: 0, 0.5, 2.5 and 5 ng 125I-EGF was dissolved in 100 Wl low-melting agarose and placed at the bot-
tom of the underwell of Transwell cell culture chambers. At several time points samples were taken from the upper well and radioactivity was
determined. The EGF concentration (nM) was calculated from the radioactivity released from the agarose, using a standard curve. B: ZR11
cells were incubated with 5 ng EGF/100 Wl agarose. At various time points the number of migrated cells was counted under a phase-contrast
microscope in 10 random ¢elds (100U magni¢cation). Corrections were made for proliferation of the migrated cells. EGF concentration (nM)
at various time points is shown.
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To study the kinetics of EGF release from the agarose, we
added 125I-labelled EGF to the agarose and took samples
from the upper chamber at di¡erent time points to measure
radioactivity. We used a standard curve to correlate the radio-
activity to the 125I-EGF concentration that resulted from the
125I-EGF release from the agarose. Only after 10 hours most
of the EGF was released (Fig. 1A), suggesting a gradual EGF
release up to 10 hours after EGF addition.
Next, we investigated whether cell migration in this system
was also a gradual event. Therefore we used human breast
cancer cells (ZR11, transfected with EGFR), since EGFR
overexpression is often found in this type of cancer. We de-
termined the number of migrated ZR11 cells after di¡erent
time intervals of EGF incubation (5 ng/100 Wl agarose, max-
imum molarity 400 nM EGF) in the presence of 10% serum.
Fig. 1B shows that the number of migrated ZR11 cells in-
creases at least until 48 h after addition of the cells to the
upper chamber. The increase in migrated cells parallels the
increase in EGF concentration, suggesting that EGF is re-
sponsible for this migration.
Furthermore, to mimic the situation in vivo we decided to
incubate the cells with EGF in the presence of 10% serum.
Proliferation of cells growing on 10% serum was the same as
for cells growing on 10% serum and additional EGF (up to 50
ng/ml, not shown). In our assays corrections are made for
proliferation of the migrated cells by dividing the cell numbers
by a factor determined in parallel proliferation experiments.
In conclusion, Fig. 1 shows that EGF is gradually released
from the agarose, resulting in an increasing EGF concentra-
tion in the culture chamber. The number of migrated cells also
gradually increases up to 48 h after the start of the experi-
ment. The breast cancer cells seem to migrate as a result of
increasing EGF concentration.
To study the e¡ect of EGFR overexpression on cell migra-
tion, ZR11 (EGFR-transfected) and ZR9b11 (mock-trans-
fected) breast tumor cells were incubated with various EGF
concentrations dissolved in 100 Wl agarose in the presence of
10% serum. After 48 h the number of migrated cells was
determined (Fig. 2A). ZR9b11 cells showed only a slight in-
crease in cell migration (up to 1.9-fold), whereas ZR11 cells
showed an increase of approximately 20-fold. Optimal migra-
tion was observed by incubation with 5 ng EGF/100 Wl. Al-
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Fig. 2. Cell migration in EGFR overexpressing human breast cancer cells. A: ZR9b11 and ZR11 cells were incubated with 0, 0.5, 5, or 25 ng
EGF/100 Wl agarose. After 48 h the number of migrated cells was counted under a phase-contrast microscope in 10 random ¢elds (100U mag-
ni¢cation). Representative experiment out of three, performed in triplicate (mean þ S.D.). B: ZR9b11 and ZR11 cells were incubated with 0 or
5 ng EGF/100 Wl agarose. In addition, ZR11 cells were incubated with 5 ng EGF/100 Wl and other factors, as indicated. After 48 h the number
of migrated cells was counted. Relative cell migration is shown, compared with the number of migrated ZR11 cells after 48 h incubation with
5 ng EGF/100 Wl.
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most no di¡erence in cell migration was seen between un-
stimulated ZR9b11 and ZR11 cells, indicating that EGFR
overexpression alone is not su⁄cient to induce cell migration.
To con¢rm that this cell migration was indeed the e¡ect of
EGF stimulation of the EGFR, we preincubated ZR11 cells
for 2 h with two di¡erent EGFR antibodies (Ab-1, Calbio-
chem, Cambridge, MA and Ab-2, Oncogene, Manhasset, NY,
recognizing di¡erent epitopes in the external domain, and in-
terfering with ligand binding). Preincubation with these anti-
EGFR antibodies decreased the number of migrated ZR11
cells (Fig. 2B), indicating that activation of EGFR by binding
of its ligand is necessary for its e¡ect on migration of human
breast cancer cells.
Activation of the EGFR leads to phosphorylation of its C-
terminus. Several SH2 domain (Src homology)-containing
proteins have been found to bind to the phosphotyrosine res-
idues of the receptor. These proteins activate di¡erent path-
ways that result in cell proliferation, di¡erentiation, motility,
and adhesion [24]. In an attempt to unravel the pathway that
is involved in migration of the human breast cancer cells, we
preincubated ZR11 cells with a series of inhibitors. We used
inhibitors of receptor tyrosine kinases, c-Src tyrosine kinases,
and tyrosine phosphatases. Unfortunately, incubation with
high concentrations of these inhibitors resulted in cell death.
In contrast, using inhibitors for MAPKK (PD 98059, EI-360,
Biomol, Plymouth, PA) and PI3K (LY 294002, ST-420, Bio-
mol or wortmannin, ST-415, Biomol), no cell death was de-
tected. Preincubation of ZR11 cells with the MAPKK inhib-
itor (10 WM, 2 h) resulted in a decrease in cell migration (2-
fold, Fig. 2B). No in£uence on ZR9B11 migration was found
(not shown). Incubation with this inhibitor did indeed result
in hypophosphorylation (and inactivation) of MAPK, as was
con¢rmed by MAPK shift assays (data not shown). These
results indicate that MAPK activation might have a positive
e¡ect on cell migration induced by EGFR activation.
When ZR11 cells were preincubated with the PI3K inhib-
itors (LY 10 WM or wortmannin 100 WM, 2 h) EGF-induced
cell migration was stimulated approximately 2-fold (Fig. 2B).
Again, no in£uence on migration of ZR9b11 cells was found.
Therefore, in contrast to MAPK, PI3K appears to have an
inhibiting e¡ect on migration of ZR11 cells in this system.
Furthermore, in the absence of EGF the inhibitors had no
e¡ect on cell migration.
To investigate whether the e¡ect of EGFR overexpression
was cell type-speci¢c, we also used NIH3T3 ¢broblasts,
HERc13 and HER14 (both transfected with wild type
EGFR [20], Table 1) in the migration assay. In these assays
we used non-ECM-coated ¢lters in the Transwell system, since
the migration of ¢broblasts was negligible using coated ¢lters.
Fig. 3A shows that the cell migration of ¢broblasts overex-
pressing EGFR is also increased upon EGF incubation. Mi-
gration of HER14 cells, with the highest amount of EGFR,
was increased approximately 2.6-fold by EGF addition,
whereas migration of HERc13 cells showed hardly any in-
crease.
Overexpression of c-erbB2 is, like EGFR, often found in
human breast cancer. Since the ligand of c-erbB2 has not been
identi¢ed so far, we used chimerae of EGFR/c-erbB2 that can
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Fig. 3. Cell migration of EGFR and c-erbB2 overexpressing NIH3T3 ¢broblasts. A: Cells (as indicated) were incubated with 0 or 5 ng EGF/
100 Wl agarose. After 48 h the number of migrated cells was counted in 10 random ¢elds under a phase-contrast microscope (100U magni¢ca-
tion). Representative experiment out of three, performed in triplicate (mean þ S.D). B: NIH3T3, H3 and 3.4 cells were incubated with tetracy-
cline (96 h, 1 Wg/ml, H3 cells show no c-erbB2 expression) or not (H3 cells overexpress c-erbB2). After 48 h the number of migrated cells was
counted in 10 random ¢elds under a phase-contrast microscope (100U magni¢cation). Representative experiment out of two, performed in trip-
licate (mean þ S.D.).
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be stimulated with EGF (NEN37 and LTR-EN2 [21], Table 1)
in our migration assay. Fig. 3A shows that even without EGF
incubation these cells migrate better than control NIH3T3
cells. Upon EGF incubation, migration of NEN37 cells was
increased 1.9-fold and migration of LTR-EN2 cells 1.7-fold.
To study whether c-erbB2 overexpression alone was su⁄-
cient for induction of cell migration we used H3 cells
(NIH3T3 cells expressing c-erbB2 under a tetracycline-respon-
sive promoter [23], Table 1). By addition of tetracycline the
expression of c-erbB2 disappears. This was con¢rmed by in-
cubation of H3 cells with tetracycline (1 Wg/ml) for di¡erent
time periods, immunoprecipitating c-erbB2 from cell lysates,
and Western blotting experiments using anti-c-erbB2 antibod-
ies. After 48 h of tetracycline incubation no c-erbB2 protein
could be detected ([23], and own observation). Additionally,
we used 3.4 cells that constitutively express c-erbB2 ([23], Ta-
ble 1). Our results show that overexpression of c-erbB2 alone
does indeed increase cell migration of NIH3T3 cells (Fig. 3B).
Without tetracycline incubation H3 cells express c-erbB2 and
show as much cell migration as the 3.4 cells. After incubation
with tetracycline (48 h preincubation and during the assay)
H3 cells do not express c-erbB2 any more and, as a conse-
quence, cell migration is comparable with NIH3T3 cells. Ad-
dition of tetracycline to NIH3T3 cells or 3.4 cells did not
a¡ect cell migration (Fig. 3B).
In conclusion, our results show that overexpression of
EGFR and c-erbB2 induces cell migration in our in vitro
model of cell migration. The e¡ect of EGFR is only found
upon activation of the receptor by EGF, while overexpression
of c-erbB2 alone appears to be su⁄cient. Furthermore, in the
human breast cancer cells both MAPK and PI3K might be
involved in cell migration induced by the EGFR.
4. Discussion
In breast cancer, as in most other solid tumors, the meta-
static phase of the disease rather than the primary lesion is the
cause of death of the majority of patients [24]. In this report
we showed that overexpression of EGFR and c-erbB2, both
prognostic factors, can induce cell migration, an important
step in the metastatic cascade. It has been reported that in
vitro invasiveness correlates with the in vivo metastatic poten-
tial of tumor cells [25].
We found that when EGF was used as a chemoattractant,
the cell migration of EGFR and EGFR/c-erbB2 chimera ex-
pressing cells was increased. Increased expression of EGFR in
metastases of human breast cancer, as compared to cells of
the primary tumor, suggests a contribution of EGFR to
breast cancer metastasis [26]. To test a causative link between
expression of EGFR and the process of metastasis Lichtner et
al. [27] introduced and expressed full length cDNA for the
human EGFR in low metastatic MTC rat mammary adeno-
carcinoma cells. These cells respond to EGF by enhanced
matrix adhesion and increased lung colonizing potential.
In our assays breast cancer cells migrate much better than
NIH3T3 ¢broblasts after addition of EGF, suggesting funda-
mental di¡erences in the intracellular events that follow the
binding of EGF to its receptor on epithelial cells and ¢bro-
blasts. Also, the magnitude of the e¡ect may be directly re-
lated to the amount of EGFR expression.
We showed that both the MAPK and PI3K pathways are
involved in EGF-induced cell migration in the breast cancer
cells. It has been described that upon PDGF activation
MAPK in£uences the cell motility by phosphorylating and
thereby enhancing myosin light chain kinase activity. This
leads to phosphorylation of myosin light chains and polymer-
ization of actin cables, resulting in enhanced cell migration
[28]. Our results suggest that in human breast cancer cells
activation of MAPK by EGFR may lead to increased cell
migration via similar pathways. MAPK is often implicated
in the Ras pathway leading to cell proliferation and di¡er-
entiation. However, mitogenic and motogenic signals may
be on a common pathway to MAPK activation and then
diverge based an the ability of MAPK to translocate to dis-
tinct intracellular compartments [29]. Indeed, MAPK has
been shown to translocate to the nucleus [29] as well as to
the cytoskeleton [30].
We found that PI3K has a negative e¡ect on EGF-induced
migration of human breast cancer cells. It has been described
that activation of PI3K increases cell matrix adhesion. Upon
stimulation of the PDGF receptor, PI3K transmits signals
that activate integrin adhesiveness [31]. The p85 subunit of
PI3K has been found to associate, in a integrin-dependent
manner, with tyrosine phosphorylated FAK [32]. In the
Transwell system, increased cell matrix adhesion may very
well lead to decreased cell migration, since we used ECM-
coated ¢lters.
Our data indicate that overexpression of c-erbB2 is su⁄-
cient to induce cell migration. From the literature it is known
that overexpression of c-erbB2 in NIH3T3 cells mediates
transformation [33]. A critical level of c-erbB2 overexpression
seems to be necessary to achieve transformation [34]. This
phenomenon can be explained by a model in which there is
an equilibrium between monomeric and oligomerized forms of
c-erbB2. As the quantity of c-erbB2 protein increases by over-
expression, the equilibrium is shifted to the oligomeric state,
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Table 1
EGFR and c-erbB2 expressing cell lines
Cell line Expression of Receptors/cell Reference
ZR9b11 EGFR 20 000 [20]
ZR11 EGFR 1 200 000 [20]
NIH3T3 EGFR 3 000 ATCC
HERc13 EGFR 65 000 [21]
HER14 EGFR 250 000 [21]
NEN37 EGFR/c-erbB2 400 000 [22]
LTR-EN2 EGFR/c-erbB2 1 400 000 [22]
H3 c-erbB2 V500 000 [23]
3.4 c-erbB2 V2 000 000 [23]
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resulting in activation of the tyrosine kinase and inappropriate
cellular signaling [35].
The process of cell migration requires the coordinated acti-
vation of both growth factor and adhesion receptor signaling.
It has been described that signals downstream of EGFR and
c-erbB2 can modulate integrin-mediated processes in both an
inhibitory and a stimulatory manner [8]. Since the observed
patterns of tyrosine phosphorylated proteins in NIH3T3 cells
transformed by EGFR or c-erbB2 are qualitatively and quan-
titatively di¡erent [36], further studies will be required to un-
ravel the pathways that lead from either EGFR or c-erbB2
overexpression to metastatic spread of tumor cells.
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